Last updated: 09 Nov, 2020 | 02:12 pm
Gland Pharma IPO to raise up to ₹6,480 crore opened for subscription today. The issue will remain open till 11th Nov 2020, Wednesday.
About Gland Pharma
Gland Pharma revenue break-up
About the issue
While the company’s financials have shown robust growth, the issue is not bereft of risks. Some of the risks are detailed below:
At the higher end of the price band of ₹1,500, Gland Pharma is available at a PE ratio of 31.7 (based on FY20 EPS). This is reasonable, given the company robust financials, positive business outlook and good return ratios. However, investors must bear in mind the risk of degradation in India-China relations, which could adversely impact the business. Hence, investors should Subscribe With Caution.